Streetbeat News

Analyst Ratings

NVDA

NVIDIA Corporation (NASDAQ:NVDA) is trading lower ahead of its Q1 2024 earnings release. Analysts estimate earnings per share of 92 cents on revenues of $6.52 billion. Citigroup analyst Atif Malik maintained a Buy rating and raised the price target from $305 to $363, while other analysts also raised their price targets.

Portfolio Pulse from Melanie Schaffer

May 24, 2023 | 7:18 pm

LFCR

Lifecore Biomedical (NASDAQ:LFCR) has received 4 somewhat bullish and 1 indifferent analyst ratings in the last quarter. The average 12-month price target is $7.8, representing a 20% decrease from the previous average of $9.75.

Portfolio Pulse from Benzinga Insights

May 24, 2023 | 7:04 pm

WOOF

Over the past 3 months, 13 analysts have published their opinions on Petco Health and Wellness (NASDAQ:WOOF) stock, with an average price target of $11.92, implying upside from the current price of $8.53. The current average has decreased by 17.45% from the previous average price target of $14.44.

Portfolio Pulse from Benzinga Insights

May 24, 2023 | 7:03 pm

AYX

In the last quarter, Alteryx (NYSE:AYX) received 5 bullish, 8 somewhat bullish, and 1 indifferent analyst ratings. The average 12-month price target is $72.0, representing a 9.35% decrease from the previous average of $79.43.

Portfolio Pulse from Benzinga Insights

May 24, 2023 | 7:02 pm

BLDR

Builders FirstSource (NYSE:BLDR) has received an average price target of $108.4 from 15 analysts over the past 3 months, a 20.44% increase from the previous average price target of $90.00. The ratings include 2 bullish, 8 somewhat bullish, and 5 indifferent.

Portfolio Pulse from Benzinga Insights

May 24, 2023 | 7:02 pm

LEN

Over the past 3 months, 7 analysts have published their opinion on Lennar (NYSE:LEN) stock, with an average 12-month price target of $115.86, an 8.62% increase from the previous average of $106.67.

Portfolio Pulse from Benzinga Insights

May 24, 2023 | 7:01 pm

LLY

PFE

ZURA

Raymond James initiated coverage on Zura Bio Limited (NASDAQ:ZURA) with a Strong Buy rating and a $20 price target. Zura has three clinical-stage inflammation & immunology drugs in development, licensed from Pfizer Inc (NYSE:PFE) and Eli Lilly And Co (NYSE:LLY). Zura Bio recently merged with JATT Acquisition Corp, raising $65 million in gross cash proceeds.

Portfolio Pulse from Vandana Singh

May 24, 2023 | 6:42 pm

DAVA

Needham analyst Mayank Tandon reiterated a Buy rating on Endava Plc (NYSE:DAVA) but lowered the price target to $68 from $90. Endava's 3Q FY23 results exceeded expectations, but growth is expected to be pressured due to ongoing macro pressure and the US regional banking crisis.

Portfolio Pulse from Nabaparna Bhattacharya

May 24, 2023 | 6:24 pm

NTR

Nutrien shares are trading lower after JP Morgan lowered its price target on the stock from $92 to $78.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 6:21 pm

COP

Unusual options activity has been observed for ConocoPhillips (NYSE:COP), with 80% bullish and 20% bearish sentiment. Whales have been targeting a price range of $105 to $115 for COP over the last 3 months. Analysts have maintained various ratings and price targets for the company.

Portfolio Pulse from Benzinga Insights

May 24, 2023 | 6:18 pm